PharmaMar has held its General Shareholders Meeting today

- **In the Meeting a dividend of €0.04 per share was agreed.**
- **A reverse split of the Company's shares at the rate of one share per every twelve was agreed.**

Madrid, June 18th, 2020.- PharmaMar (MSE:PHM) has held its Ordinary Shareholders' General Meeting today, exclusively by webinar, in which it reviewed 2019, and also explained the most important milestones for 2020, especially the recent approval of lurbinectedin in the US for the treatment of relapsed metastatic Small Cell Lung Cancer (SCLC).

Among the items on the agenda approved at the meeting, was the resolution to distribute an ordinary dividend payment of €0.04 gross for each of the Company's shares. This dividend will be paid on June 30th, 2020.

In addition, the it was agreed in the Meeting to merge together and cancel all the shares into which the Company's share capital is divided, in order to exchange them for newly issued shares in the proportion of one (1) new share per every twelve (12) old shares, increasing the unit face value of the shares from €0.05 to €0.60, without altering the Company's share capital value.

Oncology Business Unit

Lurbinectedin (Zepzelca™) has been approved this week by the US Food and Drug Administration (FDA) for the treatment of adult patients with metastatic SCLC cancer with disease progression, after platinum-based chemotherapy.

On December 19th, 2019, PharmaMar and Jazz Pharmaceuticals announced an exclusive license agreement for the marketing of lurbinectedin in the United States. Under the terms of the agreement, PharmaMar received an upfront payment of $200 million, and will receive an additional $100 million with this approval by June 30th 2020. This could be increased by up to an additional $150 million, once full approval occurs.

As already reported on December 19th, 2019, PharmaMar will receive royalties on net sales of lurbinectedin ranging from the high double digits to a maximum of 30%.

On April 28th, 2020, the Company announced the start of a clinical trial with plitidepsin (Aplidin®) for the treatment of patients with COVID-19, after having previously obtained positive results in in vitro studies conducted at the Spanish

National Center for Biotechnology at the National Center for Scientific Research (CNB-CSIC).

10 hospitals are now participating in the APLICOV-PC clinical trial. This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in COVID-19 patients requiring hospital admission.

Sylentis

Regarding the phase III Helix clinical study of tivanisiran (SYL1001) for the treatment of dry eye syndrome, the closure of the participating centers and the final report of the clinical study were completed. The next clinical trial is currently being designed for the progression of the clinical development of the product, especially aimed at patients who show more severity in the disease, such as those with Sjögren's Syndrome, since these patients, in the Helix study, showed a larger improvement in signs and symptoms.

In addition, the Company is working on new candidates based on RNAi technology for the treatment of eye allergies and retinal diseases. These new compounds have been analyzed for their effectiveness in preclinical models for these pathologies. SYL1801 for the topical treatment of Age-Related Macular Degeneration disease has completed pre-clinical regulatory toxicology studies in two animal species. The results indicate that the product has a good safety profile and no toxicological effects of SYL1801 have been found after continued administration of the product by the ocular route. During this year the design of the phase I trial for SYL1801 has been completed and this trial will be carried out during 2020.

GENOMICA

During the financial year 2019, GENOMICA completed the production of the first six units that will allow the automatic analysis of the human papillomavirus with the CLART® HPV product from GENOMICA in China. These diagnosticsare adapted to the requirements of Huasin, GENOMICA's partner in this country, and include the specific design of corporate image, as well as user software in Chinese. With this step, the first milestone of the contract signed between GENOMICA and Huasin for the distribution of CLART® HPV in China, once approved by the NMPA (National Medical Products Agency), will be fulfilled.

In addition, in 2019, GENOMICA began clinical trials for the CLART® EnteroBac and CLART® SeptiBac products in China, in collaboration with the Beijing Clear Medi-tech Co.

In 2020, GENOMICA was the first Spanish biotechnology company to have a SARS-CoV-2 diagnostic test validated at the *Instituto de Salud Carlos III* and to obtain the CE mark in Spain, with 100% sensitivity and specificity.

GENOMICA's CLART® technology has the capacity to simultaneously analyze 96 patient samples in less than 5 hours, making it a diagnostic option for screening the virus in the population of the SARS-CoV-2.

PharmaMar's investment in R&D in 2019

Investment in R&D decreased between 2018 and 2019, from €73.8 million at December 2018 to €50.6 million at December 2019. €48.7 million were invested in the Oncology area. In 2019, PharmaMar focused its investment in lurbinectedin on trials related to SCLC.

In the Diagnostic segment, there was also a reduction in R&D investment, due to the completion of the NEDXA point-of-care diagnostic technology platform project, prioritizing the developments of the traditional CLART® platform.

In 2019, Sylentis prepared designs for the new Phase III clinical trial on dry eye syndrome, after completing the Phase III Helix study for that indication.

About PharmaMar

Headquartered in Madrid, PharmaMar is a biopharmaceutical company, focused on oncology and committed to research and development which takes its inspiration from the sea to discover molecules with antitumor activity. It is a company that seeks innovative products to provide healthcare professionals with new tools to treat cancer. Its commitment to patients and to research has made it one of the world leaders in the discovery of antitumor drugs of marine origin.

PharmaMar has a pipeline of drug candidates and a robust R&D oncology program. It develops and commercializes Yondelis® in Europe and has other clinical-stage programs under development for several types of solid cancers: Zepzelca™ (lurbinectedin, PM1183), PM184 and PM14. With subsidiaries in Germany, Italy, France, Switzerland, Belgium, Austria and the United States. PharmaMar wholly owns other companies: GENOMICA, a molecular diagnostics company; Sylentis, dedicated to researching therapeutic applications of gene silencing (RNAi). To learn more about PharmaMar, please visit us at www.pharmamar.com.

Media Contact:

Alfonso Ortín – Communications Director aortin@pharmamar.com Mobile: +34 609493127
Miguel Martínez-Cava – Communication Manager mmartinez-cava@pharmamar.com Mobile: +34 606597464
Phone: +34 918466000

Capital Markets & Investor Relations:

José Luis Moreno– Capital Markets & Investor Relations Director
María Marín de la Plaza – Capital Markets & Investor Relations
investorrelations@pharmamar.com
Phone: +34 914444500

Or please visit our website at www.pharmamar.com